World

Won't take part in displacement of Palestinians, says Egypt

Jan 30, 2025

Cairo [Egypt], January 30: Egyptian President Abdel-Fattah el-Sisi said on Wednesday his country will not participate in the displacement of Palestinians, days after US President Donald Trump suggested Arab countries take in Palestinian refugees from the war-torn Gaza Strip.
"Deportation and displacement of the Palestinian people is an injustice in which we cannot participate," el-Sisi said in Cairo, in his first public remarks on Trump's call.
El-Sisi said that if he asked the Egyptian people to accept the displacement of Palestinians, "they would all take to the street and tell me not to participate in injustice," he said at a televised joint press conference with visiting Kenyan President William Ruto.
The issue affects the security of Egypt, which borders the densely populated Gaza Strip, el-Sisi said. He added that Egypt is keen on working with Trump in achieving peace based on the two-state solution.
Egypt, a US ally, was the first Arab country to sign a peace treaty with Israel in 1979.
Earlier this month, Egypt along with the United States and Qatar brokered another ceasefire in the Gaza war between Israel and the Palestinian Islamist Hamas movement after months of on-and-off negotiations.
Source: Qatar Tribune

More news

Sirolimus-Coated Balloon Matches Drug-Eluting Stent at One Year in Large International TRANSFORM II Trial

Tampa (Florida) [US], November 2: Sirolimus-coated balloon (SCB) strategy was non-inferior to contemporary everolimus-eluting stents (EES) for Target Lesion Failure (TLF) at 12 months in patients with de novo coronary artery disease. These are the results of the TRANSFORM II randomised trial, presented today as a Late-Breaking Clinical Trial at TCT 2026 and accepted in The Lancet which confirm how MagicTouch Sirolimus Coated Balloon (Concept Medical) matches contemporary best in class stent. Late-breaking results presented at TCT 2026 show an implant-free strategy with MagicTouch Sirolimus Coated Balloon is non-inferior to everolimus-eluting in de novo coronary artery disease.

Nov 02, 2026